NORTHSTAR Medical Radioisotopes and Curadh MTR Announced A strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (AC-225)
NorthStar Medical Radioisotopes and
Curadh MTR Inc., (a global Moleculary Targeted Radiotherapy focused clinical,
research and advisory organization), announced the signing of a strategic long
term supply agreement for the therapeutic radioisotope non-carrier added
(n.c.a.) Actinium-225 (Ac-225).
Under the terms of the agreement,
NorthStar will supply its high purity, n.c.a. Ac-225 to Curadh for use in its
pioneering molecularly targeted radiation (MTR) programs for the treatment of
common lethal tumors.
To read more please visit:
Source: Northstar